• Open Access

Autologous Peripheral Blood Hematopoietic Cell Transplantation in Dogs with T-Cell Lymphoma

Authors

  • E.E. Warry,

    1. Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
    Search for more papers by this author
  • J.L. Willcox,

    1. Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
    Search for more papers by this author
  • S.E. Suter

    Corresponding author
    1. Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC
    2. Center for Comparative Medicine and Translational Research, North Carolina State University, Raleigh, NC
    3. Lineberger Comprehensive Cancer Center, Chapel Hill, NC
    • Corresponding author: S.E. Suter VMD, PhD, ACVIM (Oncology) Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1051 William Moore Drive, CVM Research #308, Raleigh, NC 27607; e-mail: steven_suter@ncsu.edu.

    Search for more papers by this author

Abstract

Background

Peripheral blood hematopoietic cell transplantation (PBHCT) is a feasible treatment option for dogs with B-cell lymphoma.

Objective

To examine apheresis and PBHCT outcomes in dogs diagnosed with T-cell lymphoma (TCL).

Animals

Fifteen client-owned dogs diagnosed with high-grade TCL.

Methods

After high-dose cyclophosphamide and rhG-colony-stimulating (rhG-CSF) factor treatment, peripheral blood mononuclear cells were collected using cell separators. The harvested cells then were infused after varying doses of total body irradiation (TBI). Postirradiation adverse effects were managed symptomatically and dogs were discharged upon evidence of hematopoietic engraftment.

Results

More than 2 × 106 CD34+ cells/kg were harvested from 15/15 dogs. Thirteen of 15 (87%) dogs engrafted appropriately, whereas 2 (13%) of the dogs died in the hospital. One dog developed cutaneous B-cell lymphoma 120 days post-PBHCT. The median disease-free interval and overall survival (OS) of the 13 dogs transplanted in first remission from the time of PBHCT were 184 and 240 days, respectively. Stage and substage of disease at diagnosis had no effect on OS. Two of 13 (15%) dogs were alive 741 and 772 days post-PBHCT.

Conclusions and Clinical Importance

PBHCT may be considered as a treatment option for dogs with TCL.

Ancillary